custom tissue microarray (tma) Search Results


customized mouse oligo gearray microarray membranes  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation customized mouse oligo gearray microarray membranes
Customized Mouse Oligo Gearray Microarray Membranes, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc02593420-64-10-23?v=SuperArray+Bioscience+Corporation
Average 90 stars, based on 1 article reviews
customized mouse oligo gearray microarray membranes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
renal tissue microarray (tma  (BioChain Institute)
90
BioChain Institute renal tissue microarray (tma
Renal Tissue Microarray (Tma, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc04693247-68-6-11?v=BioChain+Institute
Average 90 stars, based on 1 article reviews
renal tissue microarray (tma - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
tissue microarrays tma  (SuperBioChips)
90
SuperBioChips tissue microarrays tma
Tissue Microarrays Tma, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc05432263-207-25-33?v=SuperBioChips
Average 90 stars, based on 1 article reviews
tissue microarrays tma - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
tissue microarray  (SuperBioChips)
90
SuperBioChips tissue microarray
Tissue Microarray, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc06435990-148-1-29?v=SuperBioChips
Average 90 stars, based on 1 article reviews
tissue microarray - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
tissue microarray (tma)  (US BIOLAB CORPORATION INC)
90
US BIOLAB CORPORATION INC tissue microarray (tma)
Tissue Microarray (Tma), supplied by US BIOLAB CORPORATION INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc04872783-170-1-5?v=US+BIOLAB+CORPORATION+INC
Average 90 stars, based on 1 article reviews
tissue microarray (tma) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
paraffin-embedded colorectal tissue microarray (tma  (Indivumed gmbh)
90
Indivumed gmbh paraffin-embedded colorectal tissue microarray (tma
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Paraffin Embedded Colorectal Tissue Microarray (Tma, supplied by Indivumed gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc06522288-179-22-26?v=Indivumed+gmbh
Average 90 stars, based on 1 article reviews
paraffin-embedded colorectal tissue microarray (tma - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
bladder cancer tissue microarrays tma  (Abcam)
94
Abcam bladder cancer tissue microarrays tma
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Bladder Cancer Tissue Microarrays Tma, supplied by Abcam, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc07730422-172-0-8?v=Abcam
Average 94 stars, based on 1 article reviews
bladder cancer tissue microarrays tma - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
tissue microarray tma br1141a  (TissueArray.com LLC)
90
TissueArray.com LLC tissue microarray tma br1141a
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Tissue Microarray Tma Br1141a, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc11557828-397-0-4?v=TissueArray.com+LLC
Average 90 stars, based on 1 article reviews
tissue microarray tma br1141a - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
tumour tissue microarrays (tma)s  (TriStar Technology Group LLC)
90
TriStar Technology Group LLC tumour tissue microarrays (tma)s
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Tumour Tissue Microarrays (Tma)s, supplied by TriStar Technology Group LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc06251026-100-0-21?v=TriStar+Technology+Group+LLC
Average 90 stars, based on 1 article reviews
tumour tissue microarrays (tma)s - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human melanoma tissue microarray tma  (Novus Biologicals)
94
Novus Biologicals human melanoma tissue microarray tma
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Human Melanoma Tissue Microarray Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc03887365-85-1-24?v=Novus+Biologicals
Average 94 stars, based on 1 article reviews
human melanoma tissue microarray tma - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
adult normal tissue ffpe tma  (Novus Biologicals)
94
Novus Biologicals adult normal tissue ffpe tma
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Adult Normal Tissue Ffpe Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/bio_rxiv__2024__12__11__627962-350-34-40?v=Novus+Biologicals
Average 94 stars, based on 1 article reviews
adult normal tissue ffpe tma - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
tissue microarrayer instrument tma master 1.14 sp3  (3DHistech ltd)
90
3DHistech ltd tissue microarrayer instrument tma master 1.14 sp3
(A) Baseline expression of selected DDR markers was demonstrated and quantified in a <t>colorectal</t> tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue <t>microarray</t> cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.
Tissue Microarrayer Instrument Tma Master 1.14 Sp3, supplied by 3DHistech ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom+tissue+microarray+%28tma%29/pmc09706716-106-28-35?v=3DHistech+ltd
Average 90 stars, based on 1 article reviews
tissue microarrayer instrument tma master 1.14 sp3 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


(A) Baseline expression of selected DDR markers was demonstrated and quantified in a colorectal tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue microarray cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers

doi: 10.1158/1078-0432.CCR-18-2523

Figure Lengend Snippet: (A) Baseline expression of selected DDR markers was demonstrated and quantified in a colorectal tissue array with 32 tumors (2 cores per case are included) and 15 normal colon tissues. At least 500 individual tumor nuclei were quantified in 95% of the tissue microarray cores. (B-C) Baseline marker quantitation in advanced stage colorectal cancers from patients enrolled in Phase 1 clinical trials at NCI. Median expression and inter-quantile range is indicated for each marker. A minimum of 4,000 individual tumor nuclei were quantitated across at least two nonadjacent slides per biopsy specimen. (D) Baseline expression in human colon adenocarcinoma patient-derived xenografts. At least 5,000 nuclei quantified per model. (E) Baseline expression of selected DDR markers was demonstrated and quantified in 8 colorectal cancer cell lines. Over 1000 individual nuclei were quantified for each cell line. (F) Inter-lesion baseline Rad51 quantitation from patients with advanced stage cancers with two biopsies each collected from the same lesion. *p< 0.05. The dashed line represents our empirically determined baseline value cutoff of 5% of cells ≥ 5 Rad51 foci per nucleus.

Article Snippet: Baseline biological variability was established for each biomarker across 64 individual cores from 32 colorectal (CRC) tumor resections contained in a paraffin-embedded colorectal tissue microarray (TMA; Indivumed, Hamburg, Germany).

Techniques: Expressing, Microarray, Marker, Quantitation Assay, Derivative Assay

Representative H&E and immunofluorescence (IFA) images from 3 patients with advanced colorectal cancer enrolled in NCI trial NCT01851369 before and 5 days after start of treatment with a DNA damaging therapeutic regimen consisting of TCR102 plus temozolomide administered orally once daily. Red scale bar represents 10 μm.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers

doi: 10.1158/1078-0432.CCR-18-2523

Figure Lengend Snippet: Representative H&E and immunofluorescence (IFA) images from 3 patients with advanced colorectal cancer enrolled in NCI trial NCT01851369 before and 5 days after start of treatment with a DNA damaging therapeutic regimen consisting of TCR102 plus temozolomide administered orally once daily. Red scale bar represents 10 μm.

Article Snippet: Baseline biological variability was established for each biomarker across 64 individual cores from 32 colorectal (CRC) tumor resections contained in a paraffin-embedded colorectal tissue microarray (TMA; Indivumed, Hamburg, Germany).

Techniques: Immunofluorescence